Home » Newsletters » BioWorld Science

BioWorld Science

March 16, 2004

View Archived Issues

Genta highlights Q4 and full year 2003 developments

Nastech gives update on clinical development of products for obesity and sexual dysfunction

Savient reviews progress during 2003

Marcus Foundation financial commitment supports ProCord study

Bionomics files patents for genetic test for severe myoclonic epilepsy of infancy

Private equity financing to fund CellCept clinical trials for autoimmune diseases

Anticalin shows promise in vitro

Oxypurinol NDA accepted for review

Italfarmaco gains Spanish license and distribution rights to palonosetron

ThromboGenics and NuVue collaborate on plasmin products for visual disorders

Canadian approval for Factive

GSK presents four related series of ALK5 inhibitors

New porphyrin-doxorubicin conjugates prepared and tested at SLIL

Vertex claims novel GSK-3 inhibitors for stroke, Alzheimer's disease, etc.

New heparanase inhibitors and their use in angiogenesis-related conditions

New VEGFR2/VEGFR3 inhibitors identified at Schering AG

New agents for breast cancer therapy designed by Ohio State U. scientists

Novel ACAT inhibitor from Sumitomo

Potent serum HDL induction by selective PPARalpha agonist

Preliminary evidence for quinacrine in Creutzfeldt-Jakob disease

Beneficial effects of anti-IL-6R therapy in rheumatoid arthritis

Capsaicin improves ischemic threshold in stable angina patients

Effective prevention of stroke and embolism with ximelagatran after atrial fibrillation

Antithrombotic effects of DX-9065a in patients with acute coronary syndrome

Antithrombotic effects of razaxaban in healthy volunteers

Phase I trial of PPI-2458 placed on hold over animal safety data

Isis and Alnylam enter RNAi therapeutics alliance

Positive opinion in Europe for use of Glucophage in children

NDA submission for Ralivia FlashDose

Cortisol modulation license agreement finalized

Milestone achievements and patient treatment with Prolieve

Interim results from phase II Alequel study

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...
IMV-101 shows promise for B-cell malignancies
BioWorld Science
IMV-101 is a new CAR T-cell therapy targeting CD19 developed by Suzhou Immunofoco Biotechnology Co. Ltd. for the potential treatment of B-cell malignancies and...